董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bernadette Connaughton | 女 | Director | 67 | 47.00万美元 | 未持股 | 2026-05-05 |
| James Lang | 男 | Director | 61 | 0.37万美元 | 未持股 | 2026-05-05 |
| Mahesh Krishnan | 男 | Director | 55 | 46.17万美元 | 未持股 | 2026-05-05 |
| Jeffrey W. Henderson | 男 | Chairman and Director | 61 | 54.00万美元 | 未持股 | 2026-05-05 |
| Barbara Duncan | 女 | Director | 61 | 49.00万美元 | 未持股 | 2026-05-05 |
| Matthew L. Posard | 男 | Director | 59 | 47.50万美元 | 未持股 | 2026-05-05 |
| Helen I. Torley | 女 | Chief Executive Officer and Director and President | 63 | 2316.62万美元 | 未持股 | 2026-05-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Snyder | 男 | Chief Compliance Officer and General Counsel and Secretary and Senior Vice President | 59 | 453.16万美元 | 未持股 | 2026-05-05 |
| Cortney Caudill | 女 | Chief Operating Officer and Senior Vice President | 49 | 320.29万美元 | 未持股 | 2026-05-05 |
| David A. Ramsay | 男 | Interim Chief Financial Officer | 61 | 101.40万美元 | 未持股 | 2026-05-05 |
| Helen I. Torley | 女 | Chief Executive Officer and Director and President | 63 | 2316.62万美元 | 未持股 | 2026-05-05 |
董事简历
中英对照 | 中文 | 英文- Bernadette Connaughton
-
Bernadette Connaughton，从2015年12月起在本公司担任董事之一。她从2014年起，在全球医药公司Bristol-Myers Squibb开始她的职业生涯，目前担任欧洲市场、加拿大和澳大利亚主管。她曾在 Bristol-Myers Squibb担任其它高级领导职位，包括：2013-2014在President-Intercontinental担任总裁；2010-2012在President-Japan, Pacific Rim -Canada 担任总裁；2006-2009在U.S. Cardiovascular/Metabolic Business Unit担任高级副总裁；2004-2005担任Primary Care Marketing高级副总裁。2014年起，在European Markets and Patient Access Committees of the European Federation of Pharmaceutical Industry Associations任职。她持有Johns Hopkins 大学的学士学位以及Pennsylvania大学的工商管理硕士学位。
Bernadette Connaughton served in senior management position at Bristol Myers Squibb Pharmaceutical Company, most recently served as president, China, Latin America, Central and Eastern Europe and Middle East. In this position, she developed the multi year strategy for the successful commercialization of a number of oncology, virology and immunology products, including Opdivo, Yervoy, Sprycel, Daklinza and Orencia. Prior to serving in that role, Ms. Connaughton served as Bristol Myers Squibb's president, European Markets, Canada and Atralia; president, Intercontinental; and president, Japan, Pacific Rim, Atralia and Canada; senior vice president, Cardiovascular and Metabolic Biness Unit, U.S.; and senior vice president, Primary Care Marketing, U.S. Ms. Connaughton also served on the European Federation of Pharmaceutical Indtry Association, Patient Access and European Markets Committees from 2014 to 2016. She received her Bachelor of Arts from Johns Hopkins University and her Master of Biness Administration from The Wharton School, University of Pennsylvania. - Bernadette Connaughton，从2015年12月起在本公司担任董事之一。她从2014年起，在全球医药公司Bristol-Myers Squibb开始她的职业生涯，目前担任欧洲市场、加拿大和澳大利亚主管。她曾在 Bristol-Myers Squibb担任其它高级领导职位，包括：2013-2014在President-Intercontinental担任总裁；2010-2012在President-Japan, Pacific Rim -Canada 担任总裁；2006-2009在U.S. Cardiovascular/Metabolic Business Unit担任高级副总裁；2004-2005担任Primary Care Marketing高级副总裁。2014年起，在European Markets and Patient Access Committees of the European Federation of Pharmaceutical Industry Associations任职。她持有Johns Hopkins 大学的学士学位以及Pennsylvania大学的工商管理硕士学位。
- Bernadette Connaughton served in senior management position at Bristol Myers Squibb Pharmaceutical Company, most recently served as president, China, Latin America, Central and Eastern Europe and Middle East. In this position, she developed the multi year strategy for the successful commercialization of a number of oncology, virology and immunology products, including Opdivo, Yervoy, Sprycel, Daklinza and Orencia. Prior to serving in that role, Ms. Connaughton served as Bristol Myers Squibb's president, European Markets, Canada and Atralia; president, Intercontinental; and president, Japan, Pacific Rim, Atralia and Canada; senior vice president, Cardiovascular and Metabolic Biness Unit, U.S.; and senior vice president, Primary Care Marketing, U.S. Ms. Connaughton also served on the European Federation of Pharmaceutical Indtry Association, Patient Access and European Markets Committees from 2014 to 2016. She received her Bachelor of Arts from Johns Hopkins University and her Master of Biness Administration from The Wharton School, University of Pennsylvania.
- James Lang
-
James Lang于2017年1月12日加入董事会。Lang先生是Eversana公司的首席执行官，Eversana公司是向生命科学行业提供全球商业服务的领先的独立供应商，目前还担任Water Street公司的执行顾问，Water Street公司是一家战略私募股权公司，专门致力于在梦百合建立市场领先的公司。他目前担任Access Group、Health Strategies Group、Alliance Life Sciences和Dohmen Life Science Services的董事会主席。他也是BioVie公司（一个发展阶段的公司，开创了针对肝硬化并发症的创新疗法）的董事。Lang先生此前曾担任Decision Resources Group的首席执行官，该公司是一家领先的梦百合研究和咨询公司，提供高价值的梦百合行业分析和见解，他在该公司帮助将公司转变为行业领导者。早些时候，他是全球领先的战略咨询公司Strategic Decisions Group的总裁，他拓展了生命科学业务，后来将其出售给了IMS Health。他是梦百合公司的活跃私人投资者和顾问，这些公司包括被Eurofins收购的波士顿心脏诊断公司和被IMS Health收购的AlphaLPACTRX公司。
James Lang Chairman of the Board of Directors since 2023 and has served as the Company's director since 2016. He is currently CEO of EVERSANA, the leading commercialization services company for the life sciences indtry. In five years since he founded EVERSANA, it is now over $1B in revenue, with more than 7,000 employees across 40 global locations. He formerly served as the CEO of Decision Resces Group (DRG), which he transformed into a leading healthcare data and analytics firm. Prior to that, Jim was CEO of IHS Cambridge Energy Research Associates (IHS CERA), a recognized leader in energy indtry subscription information products, and formerly the President of Strategic Decisions Group (SDG), a leading global strategy consultancy. Mr. Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire and an MBA with Distinction from the Tuck School of Biness. Jim Lang currently also serves as a Director at OptimizeRX (OPRX), a Nasdaq listed Company. - James Lang于2017年1月12日加入董事会。Lang先生是Eversana公司的首席执行官，Eversana公司是向生命科学行业提供全球商业服务的领先的独立供应商，目前还担任Water Street公司的执行顾问，Water Street公司是一家战略私募股权公司，专门致力于在梦百合建立市场领先的公司。他目前担任Access Group、Health Strategies Group、Alliance Life Sciences和Dohmen Life Science Services的董事会主席。他也是BioVie公司（一个发展阶段的公司，开创了针对肝硬化并发症的创新疗法）的董事。Lang先生此前曾担任Decision Resources Group的首席执行官，该公司是一家领先的梦百合研究和咨询公司，提供高价值的梦百合行业分析和见解，他在该公司帮助将公司转变为行业领导者。早些时候，他是全球领先的战略咨询公司Strategic Decisions Group的总裁，他拓展了生命科学业务，后来将其出售给了IMS Health。他是梦百合公司的活跃私人投资者和顾问，这些公司包括被Eurofins收购的波士顿心脏诊断公司和被IMS Health收购的AlphaLPACTRX公司。
- James Lang Chairman of the Board of Directors since 2023 and has served as the Company's director since 2016. He is currently CEO of EVERSANA, the leading commercialization services company for the life sciences indtry. In five years since he founded EVERSANA, it is now over $1B in revenue, with more than 7,000 employees across 40 global locations. He formerly served as the CEO of Decision Resces Group (DRG), which he transformed into a leading healthcare data and analytics firm. Prior to that, Jim was CEO of IHS Cambridge Energy Research Associates (IHS CERA), a recognized leader in energy indtry subscription information products, and formerly the President of Strategic Decisions Group (SDG), a leading global strategy consultancy. Mr. Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire and an MBA with Distinction from the Tuck School of Biness. Jim Lang currently also serves as a Director at OptimizeRX (OPRX), a Nasdaq listed Company.
- Mahesh Krishnan
-
Mahesh Krishnan，曾在肾透析服务提供商达维塔保健，Inc.担任过各种职务，包括在达维塔保健的技术和研发战略合作伙伴关系以及华盛顿特区的医疗政策等领域担任TERM0 Venture Group的联席主管，该公司是达维塔保健，Inc.的外部创新部门。自2019年5月以来，Krishnan博士还担任达维塔保健的集团研发副总裁，在担任该职务之前，Krishnan博士于2015年至2019年5月担任达维塔保健的首位国际首席医疗官。从2004年到2009年，Krishnan博士曾在跨国生物制药公司安进公司担任过各种职务，包括担任Epogen的全球开发领导并作为执行董事，负责安进所有国内产品的医疗政策。从2000年到2004年，Krishnan博士是弗吉尼亚肾脏病学集团的执业肾病学家。他在托马斯杰斐逊大学杰斐逊医学院获得医学博士学位，在宾夕法尼亚州立大学获得医学预科学士学位。他还拥有约翰霍普金斯大学的硕士学位和约翰霍普金斯大学凯里商学院的医疗保健管理硕士学位。
Mahesh Krishnan has served in vario roles at DaVita, Inc., a provider of kidney dialysis services, including service as the co lead of DaVita Venture Group, the external innovation arm of DaVita, Inc., where he is responsible for strategic partnerships in technology and research and development at DaVita, as ll as medical policy in Washington, D.C. Since May 2019, Dr. Krishnan has also served as DaVita's Group Vice President of Research and Development and prior to that role, Dr. Krishnan served as DaVita's first international Chief Medical Officer from 2015 to May 2019. From 2004 to 2009, Dr. Krishnan served in vario roles at Amgen Inc., a multinational biopharmaceutical company, including serving as the Global Development Leader for Epogen and as Executive Director, Medical Policy for all of Amgen's domestic products. From 2000 to 2004, Dr. Krishnan was a practicing nephrologist at Virginia Nephrology Group. He earned his M.D. from Jefferson Medical College at Thomas Jefferson University and his B.S. in pre medicine from The Pennsylvania State University. He also holds an M.P.H. from Johns Hopkins University and an M.B.A. in health care management from the Johns Hopkins Carey School of Biness. - Mahesh Krishnan，曾在肾透析服务提供商达维塔保健，Inc.担任过各种职务，包括在达维塔保健的技术和研发战略合作伙伴关系以及华盛顿特区的医疗政策等领域担任TERM0 Venture Group的联席主管，该公司是达维塔保健，Inc.的外部创新部门。自2019年5月以来，Krishnan博士还担任达维塔保健的集团研发副总裁，在担任该职务之前，Krishnan博士于2015年至2019年5月担任达维塔保健的首位国际首席医疗官。从2004年到2009年，Krishnan博士曾在跨国生物制药公司安进公司担任过各种职务，包括担任Epogen的全球开发领导并作为执行董事，负责安进所有国内产品的医疗政策。从2000年到2004年，Krishnan博士是弗吉尼亚肾脏病学集团的执业肾病学家。他在托马斯杰斐逊大学杰斐逊医学院获得医学博士学位，在宾夕法尼亚州立大学获得医学预科学士学位。他还拥有约翰霍普金斯大学的硕士学位和约翰霍普金斯大学凯里商学院的医疗保健管理硕士学位。
- Mahesh Krishnan has served in vario roles at DaVita, Inc., a provider of kidney dialysis services, including service as the co lead of DaVita Venture Group, the external innovation arm of DaVita, Inc., where he is responsible for strategic partnerships in technology and research and development at DaVita, as ll as medical policy in Washington, D.C. Since May 2019, Dr. Krishnan has also served as DaVita's Group Vice President of Research and Development and prior to that role, Dr. Krishnan served as DaVita's first international Chief Medical Officer from 2015 to May 2019. From 2004 to 2009, Dr. Krishnan served in vario roles at Amgen Inc., a multinational biopharmaceutical company, including serving as the Global Development Leader for Epogen and as Executive Director, Medical Policy for all of Amgen's domestic products. From 2000 to 2004, Dr. Krishnan was a practicing nephrologist at Virginia Nephrology Group. He earned his M.D. from Jefferson Medical College at Thomas Jefferson University and his B.S. in pre medicine from The Pennsylvania State University. He also holds an M.P.H. from Johns Hopkins University and an M.B.A. in health care management from the Johns Hopkins Carey School of Biness.
- Jeffrey W. Henderson
-
Jeffrey W. Henderson自2015年9月起一直是Berkshire Partners LLC（一家私人股权投资公司）的咨询主任。2005年5月至2014年11月，他曾担任Cardinal Health Inc.（一家保健服务公司）的首席财务官。加盟Cardinal Health之前，Henderson先生在Eli Lilly公司和General Motors担任多个职位，包括担任Eli Lilly Canada的总裁兼总经理，Eli Lilly公司的主管和财务，并且在英国、新加坡、加拿大和美国的General Motors担任管理职位。自2015年8月起，Henderson先生一直担任Halozyme Therapeutics Inc.的董事；自2015年8月起，担任FibroGen, Inc.的董事。Henderson学生持有Kettering University电气工程的学士学位；Harvard Business School的工商管理硕士学位。
Jeffrey W. Henderson has served as President of JWH Consulting LLC, an investment and biness advisory firm, since January 2018. From 2015 to 2019, he served as a Healthcare Advisory Director to Berkshire Partners LLC. Mr. Henderson previoly served as the Chief Financial Officer of Cardinal Health, Inc., a multinational health care services company, from May 2005 to November 2014, and in an executive capacity until his retirement from Cardinal in Augt 2015. From 1998 to 2005, Mr. Henderson held vario senior management positions at Eli Lilly and Company, a multinational pharmaceutical company, including President and General Manager, Eli Lilly Canada, Inc. and Controller and Treasurer of Eli Lilly, Inc. He received his BS in electrical engineering from Kettering University, Flint, Mich., and his MBA from Harvard Graduate School of Biness Administration and he has completed the NACD/Carnegie Mellon University CERT Certificate in Cyber Risk Oversight program for governance professionals. - Jeffrey W. Henderson自2015年9月起一直是Berkshire Partners LLC（一家私人股权投资公司）的咨询主任。2005年5月至2014年11月，他曾担任Cardinal Health Inc.（一家保健服务公司）的首席财务官。加盟Cardinal Health之前，Henderson先生在Eli Lilly公司和General Motors担任多个职位，包括担任Eli Lilly Canada的总裁兼总经理，Eli Lilly公司的主管和财务，并且在英国、新加坡、加拿大和美国的General Motors担任管理职位。自2015年8月起，Henderson先生一直担任Halozyme Therapeutics Inc.的董事；自2015年8月起，担任FibroGen, Inc.的董事。Henderson学生持有Kettering University电气工程的学士学位；Harvard Business School的工商管理硕士学位。
- Jeffrey W. Henderson has served as President of JWH Consulting LLC, an investment and biness advisory firm, since January 2018. From 2015 to 2019, he served as a Healthcare Advisory Director to Berkshire Partners LLC. Mr. Henderson previoly served as the Chief Financial Officer of Cardinal Health, Inc., a multinational health care services company, from May 2005 to November 2014, and in an executive capacity until his retirement from Cardinal in Augt 2015. From 1998 to 2005, Mr. Henderson held vario senior management positions at Eli Lilly and Company, a multinational pharmaceutical company, including President and General Manager, Eli Lilly Canada, Inc. and Controller and Treasurer of Eli Lilly, Inc. He received his BS in electrical engineering from Kettering University, Flint, Mich., and his MBA from Harvard Graduate School of Biness Administration and he has completed the NACD/Carnegie Mellon University CERT Certificate in Cyber Risk Oversight program for governance professionals.
- Barbara Duncan
-
Barbara Duncan，自2009年5月起担任Atea Pharmaceuticals, Inc.的首席财务官，自2010年起担任Atea Pharmaceuticals, Inc.的财务主管。她有着超过15年的生命科学行业经验。Duncan女士于2009年5月至2016年6月在Intercept Pharmaceuticals，Inc.担任首席财务官兼财务主管。Duncan女士自2016年6月起担任Jounce Therapeutics，Inc.董事会成员，自2016年6月起担任Adaptimmune Therapeutics PLC.董事会成员，自2016年11月起担任Obseva S.A.董事会成员，自2017年6月起担任Ovid Therapeutics，Inc.董事会成员。自2001年至2009年4月，Duncan女士担任了DOV Pharmaceutical, Inc.， 或 DOV的首席财务官后来是首席执行官，该公司是一家生物制药公司，关注中枢神经系统异常，并于2010年被Euthymics Bioscience, Inc.收购。在加入DOV之前，从1998年8月至2001年8月，Duncan女士担任了Lehman Brothers Inc.的公司财务部担任副总裁，主要为生命科学和一般工业行业提供金融咨询服务。从1994年9月至1998年8月，Duncan女士担任了SBC Warburg Dillon Read, Inc.公司财务部的助理和董事，主要关注生命科学和一般工业行业的构建兼并、资产剥离和融资。1989年至1992年间，她也在PepsiCo, Inc.的国际审计部门工作；1986年至1989年间，也是Deloitte & Touche LLP审计部门的注册会计师。Duncan女士于1985年获得了Louisiana State University的学士学位，1994年获得了 Wharton School, University of Pennsylvania的工商管理硕士学位。她早前曾担任DOV的董事，目前是Edgemont Pharmaceuticals, LLC的董事，该公司是一家私人专业制药公司，主要关注神经科学领域。Duncan女士获得了路易斯安那州立大学的文学学士学位，宾夕法尼亚大学沃顿商学院的文学硕士学位。
Barbara Duncan retired from Intercept Pharmaceuticals, Inc., a biopharmaceutical company, where she served as Chief Financial Officer and Treasurer from May 2009 to June 2016. From 2001 to 2009, Ms. Duncan held vario senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., a biotechnology company, including Chief Financial Officer and ultimately serving as Chief Executive Officer prior to DOV's sale in 2010 to Euthymics Bioscience, Inc. Prior to joining DOV, Ms. Duncan served as Vice President of Corporate Finance Global Healthcare at Lehman Brothers Inc. from 1998 to 2001, and as Director of Corporate Finance at SBC Warburg Dillon Read Inc. from 1994 to 1998. She also worked for PepsiCo, Inc. from 1989 to 1992 in its international audit division, and was a certified public accountant in the audit division of Deloitte & Touche LLP from 1986 to 1989. Ms. Duncan received her BBA from Louisiana State University and her MBA from the Wharton School of the University of Pennsylvania. - Barbara Duncan，自2009年5月起担任Atea Pharmaceuticals, Inc.的首席财务官，自2010年起担任Atea Pharmaceuticals, Inc.的财务主管。她有着超过15年的生命科学行业经验。Duncan女士于2009年5月至2016年6月在Intercept Pharmaceuticals，Inc.担任首席财务官兼财务主管。Duncan女士自2016年6月起担任Jounce Therapeutics，Inc.董事会成员，自2016年6月起担任Adaptimmune Therapeutics PLC.董事会成员，自2016年11月起担任Obseva S.A.董事会成员，自2017年6月起担任Ovid Therapeutics，Inc.董事会成员。自2001年至2009年4月，Duncan女士担任了DOV Pharmaceutical, Inc.， 或 DOV的首席财务官后来是首席执行官，该公司是一家生物制药公司，关注中枢神经系统异常，并于2010年被Euthymics Bioscience, Inc.收购。在加入DOV之前，从1998年8月至2001年8月，Duncan女士担任了Lehman Brothers Inc.的公司财务部担任副总裁，主要为生命科学和一般工业行业提供金融咨询服务。从1994年9月至1998年8月，Duncan女士担任了SBC Warburg Dillon Read, Inc.公司财务部的助理和董事，主要关注生命科学和一般工业行业的构建兼并、资产剥离和融资。1989年至1992年间，她也在PepsiCo, Inc.的国际审计部门工作；1986年至1989年间，也是Deloitte & Touche LLP审计部门的注册会计师。Duncan女士于1985年获得了Louisiana State University的学士学位，1994年获得了 Wharton School, University of Pennsylvania的工商管理硕士学位。她早前曾担任DOV的董事，目前是Edgemont Pharmaceuticals, LLC的董事，该公司是一家私人专业制药公司，主要关注神经科学领域。Duncan女士获得了路易斯安那州立大学的文学学士学位，宾夕法尼亚大学沃顿商学院的文学硕士学位。
- Barbara Duncan retired from Intercept Pharmaceuticals, Inc., a biopharmaceutical company, where she served as Chief Financial Officer and Treasurer from May 2009 to June 2016. From 2001 to 2009, Ms. Duncan held vario senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., a biotechnology company, including Chief Financial Officer and ultimately serving as Chief Executive Officer prior to DOV's sale in 2010 to Euthymics Bioscience, Inc. Prior to joining DOV, Ms. Duncan served as Vice President of Corporate Finance Global Healthcare at Lehman Brothers Inc. from 1998 to 2001, and as Director of Corporate Finance at SBC Warburg Dillon Read Inc. from 1994 to 1998. She also worked for PepsiCo, Inc. from 1989 to 1992 in its international audit division, and was a certified public accountant in the audit division of Deloitte & Touche LLP from 1986 to 1989. Ms. Duncan received her BBA from Louisiana State University and her MBA from the Wharton School of the University of Pennsylvania.
- Matthew L. Posard
-
Matthew L. Posard，为本公司的董事会带来丰富的生命科学行业销售和营销方面的经验。他现为Illumina 新兴机会业务部的高级副总裁、总经理，负责公司技术的开发，并使之应用于新市场。2006年，他加入Illumina，担任全球营销副总裁；2007-2011，他担任全球销售副总裁，成功的领导该公司进入生命科学商业市场。加入Illumina之前，他在Gen-Probe担任过各种战略和产品营销方面的职务，帮助该公司在DNA探针为基础的传染病诊断和血库市场获得领先的地位。之前，他曾负责Biosite的全球营销，帮助成功引进该公司的BNP充血性心脏衰竭的生物标志物，以及与Beckman Coulter的联合营销协作。他获得了University of California, San Diego的数量经济与决策学学士学位。
Matthew L. Posard is Founding Principal of Explore DNA, a life sciences executive consulting firm, a position he has held since March 2016. Since 2017, he has provided advisory services to CEOs for several emerging life sciences companies. From February 2017 to April 2018, Mr. Posard served as President and Chief Commercial Officer of GenePeeks, Inc., a genetic research company. From March 2015 to April 2016, he served as Chief Commercial Officer of Trovagene, Inc., a molecular diagnostic biotechnology company. From February 2006 to February 2015, he held vario commercial and general management positions at Illumina, Inc., a genomics company focing on DNA sequencing, including senior executive positions overseeing Global Sales, Marketing, and General Manager of Clinical and Consumer Genomics as ll as New and Emerging Markets. Mr. Posard holds a BA degree in Management Science from the University of San Diego. - Matthew L. Posard，为本公司的董事会带来丰富的生命科学行业销售和营销方面的经验。他现为Illumina 新兴机会业务部的高级副总裁、总经理，负责公司技术的开发，并使之应用于新市场。2006年，他加入Illumina，担任全球营销副总裁；2007-2011，他担任全球销售副总裁，成功的领导该公司进入生命科学商业市场。加入Illumina之前，他在Gen-Probe担任过各种战略和产品营销方面的职务，帮助该公司在DNA探针为基础的传染病诊断和血库市场获得领先的地位。之前，他曾负责Biosite的全球营销，帮助成功引进该公司的BNP充血性心脏衰竭的生物标志物，以及与Beckman Coulter的联合营销协作。他获得了University of California, San Diego的数量经济与决策学学士学位。
- Matthew L. Posard is Founding Principal of Explore DNA, a life sciences executive consulting firm, a position he has held since March 2016. Since 2017, he has provided advisory services to CEOs for several emerging life sciences companies. From February 2017 to April 2018, Mr. Posard served as President and Chief Commercial Officer of GenePeeks, Inc., a genetic research company. From March 2015 to April 2016, he served as Chief Commercial Officer of Trovagene, Inc., a molecular diagnostic biotechnology company. From February 2006 to February 2015, he held vario commercial and general management positions at Illumina, Inc., a genomics company focing on DNA sequencing, including senior executive positions overseeing Global Sales, Marketing, and General Manager of Clinical and Consumer Genomics as ll as New and Emerging Markets. Mr. Posard holds a BA degree in Management Science from the University of San Diego.
- Helen I. Torley
-
Helen I. Torley，总裁、首席执行官、董事。她在2014年1月加入Halozyme，担任总裁、首席执行官、董事。职业生涯期间，她领导过一些产品的成功上市，包括Kyprolis、Prolia、Sensipar、Miacalcin。之前，她曾是Onyx Pharmaceuticals Onyx的执行副总裁、首席商业官，负责Nexavar和Stivarga产品与Bayer的合作，以及Kyprolis的美国上市。她曾在 Onyx工作，负责美国以外的市场，尤其是欧洲的商业发展。加入 Onyx之前，她在Amgen担任了14年的管理职务，曾担任美国肾脏病业务部和美国骨骼健康业务部的总经理。 1997-2002，她在Bristol-Myers Squibb担任过各种高级管理职位，包括心血管疾病和代谢销售区域副总裁、心血管全球市场营销部总监。她在Sandoz/Novartis开始职业生涯，最终的职务是医疗事务副总裁，制定并实行包括肿瘤的所有治疗领域的上市后临床研究。进入这个行业之前，她在苏格兰格拉斯哥的Royal Infirmary从事医疗工作，担任风湿病科的高级常务官。她获得了University of Glasgow的医学学士学位、外科学士学位，是Royal College of Physicians （M.R.C.P）的成员。
Helen I. Torley has served as Chief Executive Officer ("CEO") of Halozyme since 2014, successfully leading the company through a critical strategic transition in 2019. Dr Torley previoly served as Chief Commercial Officer at Onyx Pharmaceuticals from 2011 2013, leading the successful launch for Kyprolis (Carfilzomib), until the acquisition of Onyx by Amgen in 2013. From 2002 2011 Dr Torley held several senior commercial positions at Amgen including Vice President and General Manager Bone Health and Vice President and General Manager Nephrology. In these positions she led the successful launches of Prolia (denosumab) and Sensipar (cinacalcet) and significantly grew Epogen (Epoetin alfa) and Aranesp (darbepoetin alfa) revenue. From 1997 2002 she held a range of senior sales and marketing leadership positions at Bristol Myers Squib. She began her indtry career at Sandoz, which merged with Ciba Geigy to become Novartis in 1996, where she held a range of positions of increasing responsibility in Clinical Development, culminating in the position of Vice President of Medical Affairs, responsible for overseeing the design and conduct of a broad portfolio of clinical studies across nephrology, rheumatology, oncology and CNS indications. She received her M.B.Ch.B. degree ( equivalent to MD) from the University of Glasgow, Scotland and her M.R.C.P from the Royal College of Physicians, Glasgow, Scotland. - Helen I. Torley，总裁、首席执行官、董事。她在2014年1月加入Halozyme，担任总裁、首席执行官、董事。职业生涯期间，她领导过一些产品的成功上市，包括Kyprolis、Prolia、Sensipar、Miacalcin。之前，她曾是Onyx Pharmaceuticals Onyx的执行副总裁、首席商业官，负责Nexavar和Stivarga产品与Bayer的合作，以及Kyprolis的美国上市。她曾在 Onyx工作，负责美国以外的市场，尤其是欧洲的商业发展。加入 Onyx之前，她在Amgen担任了14年的管理职务，曾担任美国肾脏病业务部和美国骨骼健康业务部的总经理。 1997-2002，她在Bristol-Myers Squibb担任过各种高级管理职位，包括心血管疾病和代谢销售区域副总裁、心血管全球市场营销部总监。她在Sandoz/Novartis开始职业生涯，最终的职务是医疗事务副总裁，制定并实行包括肿瘤的所有治疗领域的上市后临床研究。进入这个行业之前，她在苏格兰格拉斯哥的Royal Infirmary从事医疗工作，担任风湿病科的高级常务官。她获得了University of Glasgow的医学学士学位、外科学士学位，是Royal College of Physicians （M.R.C.P）的成员。
- Helen I. Torley has served as Chief Executive Officer ("CEO") of Halozyme since 2014, successfully leading the company through a critical strategic transition in 2019. Dr Torley previoly served as Chief Commercial Officer at Onyx Pharmaceuticals from 2011 2013, leading the successful launch for Kyprolis (Carfilzomib), until the acquisition of Onyx by Amgen in 2013. From 2002 2011 Dr Torley held several senior commercial positions at Amgen including Vice President and General Manager Bone Health and Vice President and General Manager Nephrology. In these positions she led the successful launches of Prolia (denosumab) and Sensipar (cinacalcet) and significantly grew Epogen (Epoetin alfa) and Aranesp (darbepoetin alfa) revenue. From 1997 2002 she held a range of senior sales and marketing leadership positions at Bristol Myers Squib. She began her indtry career at Sandoz, which merged with Ciba Geigy to become Novartis in 1996, where she held a range of positions of increasing responsibility in Clinical Development, culminating in the position of Vice President of Medical Affairs, responsible for overseeing the design and conduct of a broad portfolio of clinical studies across nephrology, rheumatology, oncology and CNS indications. She received her M.B.Ch.B. degree ( equivalent to MD) from the University of Glasgow, Scotland and her M.R.C.P from the Royal College of Physicians, Glasgow, Scotland.
高管简历
中英对照 | 中文 | 英文- Mark Snyder
Mark Snyder，高级副总裁、总法律顾问、首席合规官兼秘书。Snyder先生于2022年1月加入Halozyme，担任高级副总裁、总法律顾问、首席合规官和秘书。Snyder先生在法律和商业管理方面拥有30多年的经验。在2008年1月至2021年12月加入Halozyme之前，Snyder先生曾在无线通信公司Qualcomm Incorporated的法律部门担任过多个高级职位，包括2016年4月至2021年12月担任高级副总裁兼诉讼副总法律顾问，2010年10月至2016年4月担任专利顾问副总裁。在加入高通之前，斯奈德曾在无线通信公司京瓷无线公司担任首席知识产权顾问，并在两家较小的公司担任法律和商业管理职务。斯奈德先生的法律生涯始于Sheridan Ross & McIntosh律师事务所的专利律师。Snyder先生在罗切斯特大学获得化学工程学士学位，在波士顿学院卡罗尔商学院获得工商管理硕士学位。他在波士顿学院法学院获得法学博士学位。
Mark Snyder joined Halozyme in January 2022 as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary. Mr. Snyder has over 33 years of experience in legal and biness management roles. Prior to joining Halozyme, from January 2008 to December 2021, Mr. Snyder served in vario senior positions in the legal department at Qualcomm Incorporated, a wireless communications company, including his most recent positions as Senior Vice President & Deputy General Counsel, Litigation, from April 2016 to December 2021 and Vice President, Patent Counsel, from October 2010 to April 2016. Before Qualcomm, Mr. Snyder served as Lead Intellectual Property Counsel at Kyocera Wireless Corp., a wireless communications company, and has held legal and biness management roles in two smaller companies. Mr. Snyder began his legal career as a patent attorney at the law firm of Sheridan Ross & McIntosh. Mr. Snyder received his B.S. degree in chemical engineering at the University of Rochester and his M.B.A. degree from Boston College Carroll School of Biness. He received his J.D. from Boston College Law School.- Mark Snyder，高级副总裁、总法律顾问、首席合规官兼秘书。Snyder先生于2022年1月加入Halozyme，担任高级副总裁、总法律顾问、首席合规官和秘书。Snyder先生在法律和商业管理方面拥有30多年的经验。在2008年1月至2021年12月加入Halozyme之前，Snyder先生曾在无线通信公司Qualcomm Incorporated的法律部门担任过多个高级职位，包括2016年4月至2021年12月担任高级副总裁兼诉讼副总法律顾问，2010年10月至2016年4月担任专利顾问副总裁。在加入高通之前，斯奈德曾在无线通信公司京瓷无线公司担任首席知识产权顾问，并在两家较小的公司担任法律和商业管理职务。斯奈德先生的法律生涯始于Sheridan Ross & McIntosh律师事务所的专利律师。Snyder先生在罗切斯特大学获得化学工程学士学位，在波士顿学院卡罗尔商学院获得工商管理硕士学位。他在波士顿学院法学院获得法学博士学位。
- Mark Snyder joined Halozyme in January 2022 as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary. Mr. Snyder has over 33 years of experience in legal and biness management roles. Prior to joining Halozyme, from January 2008 to December 2021, Mr. Snyder served in vario senior positions in the legal department at Qualcomm Incorporated, a wireless communications company, including his most recent positions as Senior Vice President & Deputy General Counsel, Litigation, from April 2016 to December 2021 and Vice President, Patent Counsel, from October 2010 to April 2016. Before Qualcomm, Mr. Snyder served as Lead Intellectual Property Counsel at Kyocera Wireless Corp., a wireless communications company, and has held legal and biness management roles in two smaller companies. Mr. Snyder began his legal career as a patent attorney at the law firm of Sheridan Ross & McIntosh. Mr. Snyder received his B.S. degree in chemical engineering at the University of Rochester and his M.B.A. degree from Boston College Carroll School of Biness. He received his J.D. from Boston College Law School.
- Cortney Caudill
Cortney Caudill，自2023年10月起担任公司高级副总裁、首席运营官。在加入公司之前，从2019年到2023年10月，Caudill女士在生物技术公司Aeglea生物制药公司担任的职务责任越来越大，包括制造副总裁、技术运营高级副总裁，最近担任首席产品官。从2002年到2018年，她在凯姆布雷克斯生物科学、Vaxagen，Inc.、Genentech、Vetter Pharma International、Samsung Biologics、Baxalta和Eaulife NA等多家生命科学公司担任越来越多的运营职务。她在得克萨斯大学获得生物学学士学位和心理学学士学位。
Cortney Caudill has served as the Halozyme's Senior Vice President, Chief Operating Officer since October 2025 and previoly served as Senior Vice President, Chief Operations Officer since October 2023. Prior to joining Halozyme, from 2019 to October 2023, Ms. Caudill served in roles with increasing responsibility at Aeglea Biotherapeutics, Inc., a biotechnology company, including Vice President of Manufacturing, Senior Vice President, Technical Operations and most recently Chief Product Officer. From 2002 to 2018, she held operational roles of increasing responsibility at vario life sciences companies such as Cambrex Bioscience, Vaxagen, Inc., Genentech, Vetter Pharma International, Samsung Biologics, Baxalta and Eaulife NA. She received her B.S. degree in biology and her B.A. degree in psychology from the University of Texas.- Cortney Caudill，自2023年10月起担任公司高级副总裁、首席运营官。在加入公司之前，从2019年到2023年10月，Caudill女士在生物技术公司Aeglea生物制药公司担任的职务责任越来越大，包括制造副总裁、技术运营高级副总裁，最近担任首席产品官。从2002年到2018年，她在凯姆布雷克斯生物科学、Vaxagen，Inc.、Genentech、Vetter Pharma International、Samsung Biologics、Baxalta和Eaulife NA等多家生命科学公司担任越来越多的运营职务。她在得克萨斯大学获得生物学学士学位和心理学学士学位。
- Cortney Caudill has served as the Halozyme's Senior Vice President, Chief Operating Officer since October 2025 and previoly served as Senior Vice President, Chief Operations Officer since October 2023. Prior to joining Halozyme, from 2019 to October 2023, Ms. Caudill served in roles with increasing responsibility at Aeglea Biotherapeutics, Inc., a biotechnology company, including Vice President of Manufacturing, Senior Vice President, Technical Operations and most recently Chief Product Officer. From 2002 to 2018, she held operational roles of increasing responsibility at vario life sciences companies such as Cambrex Bioscience, Vaxagen, Inc., Genentech, Vetter Pharma International, Samsung Biologics, Baxalta and Eaulife NA. She received her B.S. degree in biology and her B.A. degree in psychology from the University of Texas.
- David A. Ramsay
David A. Ramsay， 自2011年6月以来，是一位董事。自2013年5月以来，是一家上市的专注于细胞外间质产品开发和商业化的生物制药公司- Halozyme Therapeutics股份有限公司的财务总监。他此前曾于2009年5月-2013年5月期间，在Halozyme担任公司发展副总裁。2003年-2009年5月期间，在Halozyme担任副总裁和财务总监。2000-2003年期间，在一家为生命科学行业提供技术为基础的销量解决方案供应商- Lathian Systems股份有限公司担任副总裁和财务总监。1998-2000年期间，曾在一家跨国特殊医药公司- Valeant Pharmaceuticals International股份有限公司 （原为ICN Pharmaceuticals股份有限公司）担任副总裁、会计和公司财务总监。他是在Deloitte & Touche开始他的职业生涯的，他此前曾在该公司获得他的注册会计师许可证书。他拥有California大学Berkeley分校的工商管理学士学位，以及Pennsylvania大学Wharton学院的工商管理硕士学位（主修财务和战略管理）。
David A. Ramsay currently serves as President and Chief Executive Officer of Strongbridge Biopharma plc NASDAQ: SBBP, a biopharmaceutical company focused on therapies that target rare diseases, a position he has held since August 2014. He also has served as a member of the board of directors of Strongbridge since September 2015. Prior to Strongbridge, from April 2013 to August 2014 Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a publicly traded global biopharmaceutical company focused on rare diseases. Prior to Insmed, Mr. Pauls worked at Shire Pharmaceuticals, a global specialty biopharmaceutical company, from 2007 to April 2013 most recently as Senior Vice President, Head of Global Commercial Operations from May 2012 to April 2013. Earlier in his career, from 1997 to 2007 Mr. Pauls held senior positions at Bristol-Myers Squibb in Brand Management and Payor Marketing and at Johnson & Johnson in various U.S. and global commercial roles. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.- David A. Ramsay， 自2011年6月以来，是一位董事。自2013年5月以来，是一家上市的专注于细胞外间质产品开发和商业化的生物制药公司- Halozyme Therapeutics股份有限公司的财务总监。他此前曾于2009年5月-2013年5月期间，在Halozyme担任公司发展副总裁。2003年-2009年5月期间，在Halozyme担任副总裁和财务总监。2000-2003年期间，在一家为生命科学行业提供技术为基础的销量解决方案供应商- Lathian Systems股份有限公司担任副总裁和财务总监。1998-2000年期间，曾在一家跨国特殊医药公司- Valeant Pharmaceuticals International股份有限公司 （原为ICN Pharmaceuticals股份有限公司）担任副总裁、会计和公司财务总监。他是在Deloitte & Touche开始他的职业生涯的，他此前曾在该公司获得他的注册会计师许可证书。他拥有California大学Berkeley分校的工商管理学士学位，以及Pennsylvania大学Wharton学院的工商管理硕士学位（主修财务和战略管理）。
- David A. Ramsay currently serves as President and Chief Executive Officer of Strongbridge Biopharma plc NASDAQ: SBBP, a biopharmaceutical company focused on therapies that target rare diseases, a position he has held since August 2014. He also has served as a member of the board of directors of Strongbridge since September 2015. Prior to Strongbridge, from April 2013 to August 2014 Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a publicly traded global biopharmaceutical company focused on rare diseases. Prior to Insmed, Mr. Pauls worked at Shire Pharmaceuticals, a global specialty biopharmaceutical company, from 2007 to April 2013 most recently as Senior Vice President, Head of Global Commercial Operations from May 2012 to April 2013. Earlier in his career, from 1997 to 2007 Mr. Pauls held senior positions at Bristol-Myers Squibb in Brand Management and Payor Marketing and at Johnson & Johnson in various U.S. and global commercial roles. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.
- Helen I. Torley
Helen I. Torley，总裁、首席执行官、董事。她在2014年1月加入Halozyme，担任总裁、首席执行官、董事。职业生涯期间，她领导过一些产品的成功上市，包括Kyprolis、Prolia、Sensipar、Miacalcin。之前，她曾是Onyx Pharmaceuticals Onyx的执行副总裁、首席商业官，负责Nexavar和Stivarga产品与Bayer的合作，以及Kyprolis的美国上市。她曾在 Onyx工作，负责美国以外的市场，尤其是欧洲的商业发展。加入 Onyx之前，她在Amgen担任了14年的管理职务，曾担任美国肾脏病业务部和美国骨骼健康业务部的总经理。 1997-2002，她在Bristol-Myers Squibb担任过各种高级管理职位，包括心血管疾病和代谢销售区域副总裁、心血管全球市场营销部总监。她在Sandoz/Novartis开始职业生涯，最终的职务是医疗事务副总裁，制定并实行包括肿瘤的所有治疗领域的上市后临床研究。进入这个行业之前，她在苏格兰格拉斯哥的Royal Infirmary从事医疗工作，担任风湿病科的高级常务官。她获得了University of Glasgow的医学学士学位、外科学士学位，是Royal College of Physicians （M.R.C.P）的成员。
Helen I. Torley has served as Chief Executive Officer ("CEO") of Halozyme since 2014, successfully leading the company through a critical strategic transition in 2019. Dr Torley previoly served as Chief Commercial Officer at Onyx Pharmaceuticals from 2011 2013, leading the successful launch for Kyprolis (Carfilzomib), until the acquisition of Onyx by Amgen in 2013. From 2002 2011 Dr Torley held several senior commercial positions at Amgen including Vice President and General Manager Bone Health and Vice President and General Manager Nephrology. In these positions she led the successful launches of Prolia (denosumab) and Sensipar (cinacalcet) and significantly grew Epogen (Epoetin alfa) and Aranesp (darbepoetin alfa) revenue. From 1997 2002 she held a range of senior sales and marketing leadership positions at Bristol Myers Squib. She began her indtry career at Sandoz, which merged with Ciba Geigy to become Novartis in 1996, where she held a range of positions of increasing responsibility in Clinical Development, culminating in the position of Vice President of Medical Affairs, responsible for overseeing the design and conduct of a broad portfolio of clinical studies across nephrology, rheumatology, oncology and CNS indications. She received her M.B.Ch.B. degree ( equivalent to MD) from the University of Glasgow, Scotland and her M.R.C.P from the Royal College of Physicians, Glasgow, Scotland.- Helen I. Torley，总裁、首席执行官、董事。她在2014年1月加入Halozyme，担任总裁、首席执行官、董事。职业生涯期间，她领导过一些产品的成功上市，包括Kyprolis、Prolia、Sensipar、Miacalcin。之前，她曾是Onyx Pharmaceuticals Onyx的执行副总裁、首席商业官，负责Nexavar和Stivarga产品与Bayer的合作，以及Kyprolis的美国上市。她曾在 Onyx工作，负责美国以外的市场，尤其是欧洲的商业发展。加入 Onyx之前，她在Amgen担任了14年的管理职务，曾担任美国肾脏病业务部和美国骨骼健康业务部的总经理。 1997-2002，她在Bristol-Myers Squibb担任过各种高级管理职位，包括心血管疾病和代谢销售区域副总裁、心血管全球市场营销部总监。她在Sandoz/Novartis开始职业生涯，最终的职务是医疗事务副总裁，制定并实行包括肿瘤的所有治疗领域的上市后临床研究。进入这个行业之前，她在苏格兰格拉斯哥的Royal Infirmary从事医疗工作，担任风湿病科的高级常务官。她获得了University of Glasgow的医学学士学位、外科学士学位，是Royal College of Physicians （M.R.C.P）的成员。
- Helen I. Torley has served as Chief Executive Officer ("CEO") of Halozyme since 2014, successfully leading the company through a critical strategic transition in 2019. Dr Torley previoly served as Chief Commercial Officer at Onyx Pharmaceuticals from 2011 2013, leading the successful launch for Kyprolis (Carfilzomib), until the acquisition of Onyx by Amgen in 2013. From 2002 2011 Dr Torley held several senior commercial positions at Amgen including Vice President and General Manager Bone Health and Vice President and General Manager Nephrology. In these positions she led the successful launches of Prolia (denosumab) and Sensipar (cinacalcet) and significantly grew Epogen (Epoetin alfa) and Aranesp (darbepoetin alfa) revenue. From 1997 2002 she held a range of senior sales and marketing leadership positions at Bristol Myers Squib. She began her indtry career at Sandoz, which merged with Ciba Geigy to become Novartis in 1996, where she held a range of positions of increasing responsibility in Clinical Development, culminating in the position of Vice President of Medical Affairs, responsible for overseeing the design and conduct of a broad portfolio of clinical studies across nephrology, rheumatology, oncology and CNS indications. She received her M.B.Ch.B. degree ( equivalent to MD) from the University of Glasgow, Scotland and her M.R.C.P from the Royal College of Physicians, Glasgow, Scotland.